Equities

El En SpA

El En SpA

Actions
Health CareMedical Equipment and Services
  • Price (EUR)12.17
  • Today's Change-0.10 / -0.81%
  • Shares traded134.47k
  • 1 Year change+26.18%
  • Beta1.4250
Data delayed at least 15 minutes, as of Nov 22 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year El En SpA's net income fell -12.47% from 55.11m to 48.24m despite relatively flat revenues. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 23.27% to 25.05%.
Gross margin40.03%
Net profit margin7.68%
Operating margin10.32%
Return on assets7.02%
Return on equity14.64%
Return on investment12.89%
More ▼

Cash flow in EURView more

In 2023, cash reserves at El En SpA fell by 31.77m. However, the company earned 12.22m from its operations for a Cash Flow Margin of 1.77%. In addition the company used 16.97m on investing activities and also paid 24.79m in financing cash flows.
Cash flow per share0.7835
Price/Cash flow per share15.79
Book value per share4.49
Tangible book value per share4.33
More ▼

Balance sheet in EURView more

El En SpA has a Debt to Total Capital ratio of 18.45%, a higher figure than the previous year's 10.67%.
Current ratio1.90
Quick ratio1.19
Total debt/total equity0.2442
Total debt/total capital0.1845
More ▼

Growth rates in EUR

Year on year, growth in earnings per share excluding extraordinary items dropped -12.57%. Additionally, five year annualized earnings per share growth ranks highest in its industry.
Div yield(5 year avg)--
Div growth rate (5 year)--
Payout ratio (TTM)67.48%
EPS growth(5 years)23.52
EPS (TTM) vs
TTM 1 year ago
-5.31
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.